New pill aims to tame inflammation in ALS
NCT ID NCT07396818
First seen Feb 11, 2026 · Last updated Jun 21, 2026 · Updated 32 times
Summary
This early-phase trial tests an oral drug called Kamlanoflast in 40 people with ALS. The goal is to see if it is safe, tolerable, and can reduce inflammation or slow decline in function over 24 weeks. It is not yet recruiting and is a combined Phase 1/2 study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Kamlanoflast (oral drug)
What this could lead to
If successful, this could point toward a new treatment to slow ALS progression by reducing inflammation.
What could go wrong
This is a very early, small trial (40 people) testing safety and biological effects. It may not show clear benefit, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.